Can impaired liver or kidney function alter toxicant handling and increase susceptibility to adverse effects?

Impaired liver or kidney function can meaningfully change how the body processes and clears environmental chemicals, drugs, and other xenobiotics. The core claim is well established for toxicant disposition; whether this translates into greater clinical harm depends on the specific substance and organ dysfunction.

Established handling pathways

• Liver: Phase I oxidation, reduction, and hydrolysis, followed by Phase II reactions such as glucuronidation, sulfation, and glutathione conjugation, commonly make compounds more water-soluble and facilitate elimination. The liver also secretes xenobiotics and metabolites into bile for intestinal/fecal elimination.
• Kidneys: Glomerular filtration plus tubular secretion and reabsorption govern urinary clearance, particularly for small water-soluble toxicants and metabolites. Reduced kidney function can therefore retain renally cleared compounds. A low urinary concentration may reflect impaired excretion rather than low internal burden.

Mechanistic and clinical implications

• Hepatic dysfunction can alter enzyme activity, hepatic blood flow, protein binding, and biliary transport; renal dysfunction can reduce filtration and tubular secretion. These changes can shift concentrations of both parent compounds and metabolites.
• Biotransformation is not synonymous with detoxification. Metabolism can produce reactive, more toxic intermediates, so reduced hepatic metabolism may either increase parent-compound retention or reduce bioactivation, depending on the chemical.
• For cadmium, lead, arsenic, and mercury, reduced renal elimination and direct kidney toxicity may create a reinforcing cycle. Lead has been assessed as causally related to impaired renal function, including at relatively low adult exposures.

Interpretation in an older adult

• At age 77, organ function and concurrent medications are particularly relevant, but an eGFR of 60–89 alone does not establish chronic kidney disease or demonstrate increased toxicant levels. Cirrhosis often reduces hepatic clearance, whereas effects of other liver conditions vary.

Bottom line

• The liver and kidneys are central to toxicant metabolism and elimination, and impairment reliably alters handling. Increased adverse-effect susceptibility is biologically plausible but must be assessed chemical-by-chemical, considering clearance route, dose, and severity/cause of hepatic or renal dysfunction.